⑤ Founding member… Biosimilar development and consignment production business model foundation
[팍스넷뉴스 민승기 기자] As Celltrion Group Chairman Seo Jeong-jin announced’retirement from work’ on December 31, 2020, Celltrion CEO Ki Woo-sung (Vice Chairman) and Celltrion Healthcare CEO Kim Hyung-ki (Vice Chairman) are expected to lead the group’s future.
Vice-Chairman Ki and Vice-Chairman Kim will continue to serve as CEOs of Celltrion and Celltrion Healthcare, respectively, even after Seo’s retirement.
Vice Chairman Ki plans to take the lead in achieving the’Celltrion Group Vision 2030′, which will invest 40 trillion won by 2030 to grow Korea into the center of the global bio-chemical drug industry. Vice-Chairman Kim took the role of growing Celltrion Healthcare into a global comprehensive pharmaceutical bio company by solidifying the global sales and global direct sales system of Corona 19 antibody treatment.
The two vice-chairmen are the founding members of Celltrion, who have worked with Seo and Daewoo Motors.
Born in Seodaemun-gu, Seoul, Vice Chairman Ki majored in industrial engineering at Middle East High School and Hanyang University. After working in the planning office of Daewoo Motors in 1998, he joined Nexol, the predecessor of Celltrion Holdings, when Celltrion was founded in 2002. In 2007, he moved to Celltrion Production Support Division and began working at Celltrion.
Vice-Chairman Ki led the promotion of CMO (consignment production) business through the construction of large-scale biopharmaceutical production facilities such as the 1st and 2nd factories in Songdo, Incheon in the early stages of the establishment. Eventually, in 2007, it achieved the achievement of acquiring the first cGMP (Current Good Manufacturing Practice) certification for production facilities in Asia from the US Food and Drug Administration (FDA).
In addition, in 2012, when Vice Chairman Ki served as the head of Celltrion’s management support division, it was evaluated that he contributed to obtaining a product license for the world’s first antibody biosimilar’Remsima’ from the Korea Food and Drug Administration.
Since then, Vice Chairman Ki was appointed as CEO of Celltrion in 2015 and Vice Chairman of Celltrion in 2018. While serving as the CEO, he led the product approval of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for biopharmaceuticals developed by Celltrion such as Remsima, Truxima, Hezuma, and Remsima SC.
Another founding member, Vice-Chairman Kim Hyung-ki, is classified as a close close to Seo’s new appointment. Vice Chairman Kim also worked with Chairman Seo and Daewoo Motors. After serving as a director at Nexol, he began working at Celltrion in 2005, serving as Head of Celltrion’s New Business Division.
Vice-Chairman Kim led the completion of the 50,000-liter Celltrion Plant 1 in Celltrion, laying the foundation for the biopharmaceutical CMO (consignment production) business model. In addition, it is evaluated that it laid the foundation for the growth of Celltrion Group by successfully leading Celltrion’s listing on the KOSDAQ in 2008 and attracting large-scale investments from Singapore sovereign wealth fund Temasek in 2010.
After that, Vice Chairman Kim took office as CEO of Celltrion in 2015, and during his tenure, he led the product approvals of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for biopharmaceuticals developed by Celltrion such as Remsima and Truxima during his tenure.
In 2018, he moved to Celltrion Healthcare, which is in charge of marketing and distribution of biopharmaceuticals, and was appointed Vice-Chairman of the CEO, leading the expansion of sales in Europe and Europe of major products such as Remsima, Truxima, Herzuma, and Remsima SC. did.
ⒸLook at the market with new eyes. Unauthorized distribution of Paxnet News is prohibited